Welcome to our dedicated page for Flora Growth news (Ticker: FLGC), a resource for investors and traders seeking the latest updates and insights on Flora Growth stock.
Flora Growth Corp. (NASDAQ: FLGC), which has obtained shareholder approval to rebrand as ZeroStack, generates news that reflects its transition into a decentralized AI treasury company and its ongoing role as a global pharmaceutical distributor. Company announcements emphasize its strategy of accumulating $0G, the native cryptocurrency of the 0G AI infrastructure project, and its intention to position itself as a publicly listed 0G treasury.
Recent news releases highlight several themes. Flora has reported multiple private placement transactions involving common shares, pre-funded warrants, common share purchase warrants and convertible notes, with proceeds and tokens earmarked for its digital asset treasury strategy linked to $0G. The company has also announced specific purchases of $0G tokens, describing these as milestones in its mission to provide equity-based exposure to decentralized AI.
Corporate governance and capital markets developments are another recurring news topic. Flora has issued updates on its 2025 Annual and Special Meeting of Shareholders and a subsequent Special Meeting, where shareholders voted on director elections, amendments to the 2022 Incentive Compensation Plan, a share consolidation authority, a forward share split authority, the name change to ZeroStack, and approvals related to private placement issuances. The company has also reported on its 1-for-39 share consolidation and its successful effort to regain compliance with Nasdaq’s minimum bid price requirement.
Operational and strategic updates appear in news about Flora’s appointment of BitGo Trust Company, Inc. as custodian for its $0G treasury and its establishment of a crypto portfolio that includes Ethereum, Solana, Sui and Ripple. Other communications discuss its pharmaceutical distribution activities in Europe and its interest in German cannabis regulatory developments. Investors and observers can use this news feed to follow how Flora’s decentralized AI treasury strategy, financing activities, governance decisions and pharmaceutical distribution initiatives evolve over time.
Flora Growth (NASDAQ:FLGC) has successfully completed its acquisition of Franchise Global Health (TSXV:FGH) as of December 23, 2022. This transformative deal enhances Flora's presence in Germany's medical cannabis market, enabling sales across over 1,200 pharmacies and potential cannabis distribution throughout 28 countries. For the nine-month period ending September 30, 2022, Flora reported revenues of $25.7 million and gross profits of $11.5 million, while FGH reported C$42 million in revenues. The acquisition is poised to expand Flora's distribution network, creating new opportunities in the EU market.
Flora Growth Corp. (NASDAQ: FLGC) announced a registered direct offering of 12.5 million common shares and warrants to purchase an equal number of shares. The offering price is $0.40 per share and warrant, raising approximately $5.0 million in gross proceeds. The funds will be allocated for capital expenditures, increasing operating capacity, working capital, and general corporate purposes. The offering is expected to close around December 13, 2022, subject to customary conditions. Alliance Global Partners is the sole placement agent for the offering.
Flora Growth Corp. (NASDAQ: FLGC) reported substantial revenue growth for Q3 2022, with revenue reaching $10.8 million, a 414% increase year-over-year. For the nine-month period, revenue totaled $25.7 million, up 510%. Gross profit also saw impressive growth, rising 703% to $5.0 million, improving gross margins to 46.2%. The company reaffirmed its revenue guidance for 2022, expecting $35 million - $45 million. Flora has signed an agreement to acquire Franchise Global Health, enhancing its international presence in the cannabis market.
Flora Growth Corp. (NASDAQ: FLGC) has announced the completion of Flora Lab 4, a new laboratory in
Flora Growth Corp. (NASDAQ: FLGC) announced that over 73% of Franchise Global Health Inc. (TSXV: FGH) shareholders support Flora's acquisition of FGH, set for a vote on December 13, 2022. This acquisition is viewed as highly beneficial, potentially enhancing Flora's presence in Germany and the broader EU cannabis market. The transaction involves Flora issuing approximately 36.5 million to 43.5 million shares to FGH shareholders, who will face a 90-day selling restriction. Positive shareholder feedback has been noted, reinforcing confidence in this strategic move.
Flora Growth Corp. (NASDAQ: FLGC) will host an analyst call on October 26, 2022, at 2:00 p.m. EST. The call will discuss the recent acquisition of Franchise Global Health and strategic growth opportunities in the cannabis market. Analysts can pre-register by contacting ir@floragrowth.com. The webcast will be available at this link and archived on their website approximately 24 hours post-event. The call is part of Flora's commitment to transparency and engagement with its stakeholders.
Flora Growth Corp. (NASDAQ: FLGC) has signed an agreement to acquire Franchise Global Health Inc. (TSXV: FGH), expanding its footprint in the European medical cannabis market. The acquisition will allow Flora to distribute Colombian cannabis directly to German pharmacies, encompassing 1,200 pharmacies and 28 additional countries. With FGH's reported revenue of CA$30.1 million and gross profit of CA$2.1 million in the first half of 2022, Flora anticipates annual synergies of at least US$3 million post-acquisition. Regulatory approvals from the Supreme Court of British Columbia and FGH shareholders are required for completion.
Flora Growth Corp. (NASDAQ: FLGC) announced the successful export of its high-CBD dried cannabis flower to Switzerland and the Czech Republic, along with its first shipment of CBD isolate to the United States. CEO Luis Merchan highlighted this milestone as a testament to the growing demand for its Colombian products. The global CBD market is projected to surge to US$47 billion by 2028. The company also launched a commercial website for buyers to access its cannabis offerings.
Flora Growth Corp. (NASDAQ: FLGC) has been awarded the Best M&A Deal at Benzinga’s 2022 Cannabis Capital Conference in Chicago. This recognition highlights the company's strategic objectives, particularly the acquisition of JustCBD in February 2022, which added an established brand with over 300 products and a customer base exceeding 300,000. JustCBD generated US$28 million in audited revenue and US$7 million in EBITDA for fiscal year 2020. Flora executives will also be present at the conference to discuss the company’s growth and product offerings.
Flora Growth Corp. (NASDAQ: FLGC) has acquired substantially all assets of No Cap Hemp Co. without upfront payment. Instead, Flora will remit 10% of gross sales, capped at $2M, providing an immediate revenue stream. This acquisition enhances Flora's distribution in the US and adds approximately 75 SKUs, including the 'No Cap' and 'Moonblunt' trademarks. The deal aims to leverage No Cap's gas infusion technology and expand Flora's product portfolio, particularly in flower and smokeables, aligning with Flora's growth strategy.
FAQ
What is the current stock price of Flora Growth (FLGC)?
What is the market cap of Flora Growth (FLGC)?
